International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 8, Issue 2 (March-April 2026) Submit your research before last 3 days of April to publish your research paper in the issue of March-April.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 8 Issue 2
March-April 2026

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

RNA as Medicine: The Pharmacological Revolution of Therapeutic Oligonucleotides- A Review article

Author(s) Dr. Puneet Kashyap, Dr. Gunjan Khurana, Prof. Dr. Biswadeep Das, Prof. Dr. Manisha Bisht
Country India
Abstract Therapeutic oligonucleotides have matured into clinically validated medicines across neurology, hepatic/metabolic disease, cardiometabolic risk, and infectious disease. Antisense oligonucleotides (ASOs) act via RNase H–mediated degradation or splice modulation, with intrathecal splice-switching improving motor outcomes in spinal muscular atrophy and exhibiting month-scale CNS tissue half-lives. Gapmer ASOs that suppress transthyretin (TTR) synthesis deliver meaningful neuropathy improvements but require platelet and renal monitoring consistent with phosphorothioate backbones. Small interfering RNAs (siRNA) achieve potent, durable hepatic gene silencing through two delivery paradigms: subcutaneous N-acetylgalactosamine (GalNAc) conjugates with short plasma but long hepatic residence enabling quarterly to twice-yearly maintenance, and intravenous lipid nanoparticles (LNPs) that provide efficient hepatic uptake with manageable infusion reactions. Clinically, this translates to large attack reductions in acute hepatic porphyria, sustained ~50% LDL-C lowering with twice-yearly dosing in hypercholesterolemia, and ~90% TTR reduction with functional benefit in amyloidosis. mRNA vaccines using N1-methylpseudouridine and LNPs demonstrated rapid design-to-clinic timelines and high efficacy at population scale, establishing a manufacturable platform now extending toward therapeutic mRNA applications. Safety profiles largely reflect chemistry and delivery and are mitigable by sequence design, dosing strategies, premedication (for IV LNPs) - and routine laboratory monitoring. Extrahepatic targeting, stereo-controlled chemistries that enhance the potency without class toxicity and model based interval selection can expand organ reach and therapeutic breadth.
Keywords Therapeutic oligonucleotides; antisense oligonucleotides; siRNA; lipid nanoparticles; pharmacokinetics/pharmacodynamics.
Field Medical / Pharmacy
Published In Volume 8, Issue 1, January-February 2026
Published On 2026-02-27
DOI https://doi.org/10.36948/ijfmr.2026.v08i01.70023
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 8 Isu 2Cover Page Vol 8 Isu 1Cover Page Vol 7 Isu 6

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com
Powered by Sky Research Publication and Journals